2,861,825 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Bought by Acorn Capital Advisors LLC

Acorn Capital Advisors LLC purchased a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 2,861,825 shares of the company's stock, valued at approximately $22,408,000. Y-mAbs Therapeutics accounts for about 12.3% of Acorn Capital Advisors LLC's holdings, making the stock its 2nd largest position. Acorn Capital Advisors LLC owned approximately 6.39% of Y-mAbs Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Barclays PLC increased its stake in shares of Y-mAbs Therapeutics by 433.4% in the third quarter. Barclays PLC now owns 69,222 shares of the company's stock worth $910,000 after acquiring an additional 56,244 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at about $267,000. JPMorgan Chase & Co. increased its position in Y-mAbs Therapeutics by 10.4% during the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company's stock worth $399,000 after acquiring an additional 2,854 shares during the period. SG Americas Securities LLC boosted its holdings in Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock valued at $139,000 after purchasing an additional 4,163 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Y-mAbs Therapeutics by 1.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company's stock worth $2,228,000 after purchasing an additional 4,963 shares during the last quarter. Institutional investors and hedge funds own 70.85% of the company's stock.

Analyst Ratings Changes

YMAB has been the topic of several research reports. Truist Financial lowered their price target on Y-mAbs Therapeutics from $21.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday, March 5th. HC Wainwright cut their target price on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, March 21st. Bank of America cut shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a research report on Tuesday, April 22nd. Morgan Stanley cut their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research note on Wednesday, March 5th. Finally, Wedbush reissued an "outperform" rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. Two analysts have rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $17.40.

Y-mAbs Therapeutics Stock Up 2.3 %

NASDAQ YMAB traded up $0.09 during trading on Wednesday, reaching $3.95. 82,213 shares of the stock traded hands, compared to its average volume of 325,037. The stock's 50-day moving average price is $4.65 and its 200 day moving average price is $7.65. The firm has a market cap of $178.84 million, a price-to-earnings ratio of -7.32 and a beta of 0.53. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $3.84 and a fifty-two week high of $17.47.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. During the same period in the previous year, the business posted ($0.02) EPS. Analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the transaction, the insider now owns 202,721 shares of the company's stock, valued at approximately $1,060,230.83. The trade was a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 22.50% of the stock is owned by insiders.

Y-mAbs Therapeutics Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.